Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial

Pierre‐François Laterre, Peter Pickkers, Gernot Marx, Xavier Wittebole, Ferhat Meziani, Thierry Dugernier, Vincent Huberlant, Tobias Schuerholz, Bruno François, Jean-Baptiste Lascarrou, Albertus Beishuizen, Haikel Oueslati, Damien Contou, Oscar Hoiting, Jean-Claude Lachérade, Benjamin G. Chousterman, Julien Pottecher, Michael Bauer, Thomas Godet, Mahir Karakas, Julie Helms, Andreas Bergmann, Jens Zimmermann, Kathleen M. Richter, Oliver Hartmann, Melanie Pars, Alexandre Mebazaa, the AdrenOSS-2 study participants, Diego Castanares‐Zapatero, Christine Collienne, Ludovic Gèrards, Phillipe Hantson, Virginie Montiel, Caroline Berghe, M Dujardin, Leslie Gielens, Suzanne Renard, Philippe G. Jorens, Pierre Asfar, Gaëtan Plantefève, Jacques Duranteau, Emmanuel Weiss, Constance Vuillard, Anne-Laure Fedou, Marine Goudelin, Bruno Evrard, Thomas Daix, Arnaud Desachy, Philippe Vignon, Anne-Aurore Duchambon, Ludmila Baudrillart, P Bourzeix, Alexandra Gay, Céline Prevost, Coralie Chalot, Isabelle Herafa, P. Engels, Martin Maëlle, Lila-Fariza Abeud, Laure Berton, Kamilė Čerlinskaitė‐Bajorė, Nicolas Deye, Marie-Céline Fournier, Tassadit Hadjam, Alexa Hollinger, Tuija Javanainen, Clément Jourdaine, Matthieu Legrand, Badr Louadah, Arthur Neuschwander, Raphaël Clère-Jehl, Julien Demiselle, Hamid Merdji, Alexandra Monnier, Emmanuelle Mercier, Stefan Kluge, Alexander Zarbock, Arthur R. H. van Zanten, Wytze Vermeijden, Tom Dormans